Overview
- The company raised peak sales guidance for breast cancer drug Kisqali to at least $10 billion and for leukemia therapy Scemblix to at least $4 billion.
- Management reaffirmed a core operating income margin goal of at least 40% by 2029 after a 1–2 percentage point dilution from the Avidity acquisition.
- Novartis expects the $12 billion Avidity Biosciences deal to close in the first half of 2026, adding muscle-disorder candidates to the pipeline.
- Eight approved medicines are now flagged with individual peak-sales potential of $3 billion to $10 billion as pillars for mid-term growth.
- The company previously said Avidity would lift projected 2024–2029 annual sales growth to 6% from 5% following investor concern over weaker recent margins and erosion of older products such as Entresto.